Based on data collected from different sources by our team,
there are indicators that suggest that this company is no longer active. However, this information may not be accurate.
If you believe this information should be updated, please .
For more details, you can read our .
5/2013 not set
Surpass Medical
Surpass Medical Overview
Surpass Medical is developing and commercializing next-generation flow diversion technology to treat brain aneurysms using a unique mesh design and delivery system. Overview. The Surpass NeuroEndoGraft represents the next-generation flow diversion device and delivery system designed to improve ease-of-use and safe and reliable patient outcomes. Historically, intracranial aneurysms have been treated with surgical clipping or coils. These approaches have limited efficacy, particularly in complex anatomies. The Surpass team believes that flow diverters provide a valuable therapeutic alternative to patients. Technology. The Surpass device is designed to occlude a brain aneurysm by redirecting blood flow, allowing the blood in the aneurysm sac to clot. The device is implanted through a minimally invasive catheter-based procedure. The fine wire braided device is designed to be sufficiently permeable to enable sustained blood flow into side branches, remodeling the arterial lumen and repairing the diseased arterial segment while preserving side branches. The device is made from a fine cobalt chromium self-expanding braided wire mesh. Twelve platinum wires are integrated to provide excellent radiopacity. The over-the-wire delivery system allows a choice of .014 micro-guidewires. The stentgraft is preloaded into a custom-designed microcatheter, creating a device that is highly stable and predictable, with remarkable reproducibility.
Surpass Medical Climate Tech relevance
undefined
Companies you might be interested in
Driven by Finder AI
Latest News
No Data, yet.
Sorry, no content found under this section.
Oct 16, 2012
www.mlive.com
Stryker Corp. to purchase Surpass Medical for $135 million